About tg therapeutics inc. - TGTX
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
TGTX At a Glance
TG Therapeutics, Inc.
3020 Carrington Mill Boulevard
Morrisville, North Carolina 27560
| Phone | 1-212-554-4484 | Revenue | 616.29M | |
| Industry | Pharmaceuticals: Major | Net Income | 447.18M | |
| Sector | Health Technology | 2025 Sales Growth | 87.319% | |
| Fiscal Year-end | 12 / 2026 | Employees | 399 | |
| View SEC Filings |
TGTX Valuation
| P/E Current | 11.543 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 10.76 |
| Price to Sales Ratio | 7.808 |
| Price to Book Ratio | 7.144 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 39.288 |
| Enterprise Value to Sales | 7.989 |
| Total Debt to Enterprise Value | 0.052 |
TGTX Efficiency
| Revenue/Employee | 1,544,578.947 |
| Income Per Employee | 1,120,749.373 |
| Receivables Turnover | 2.016 |
| Total Asset Turnover | 0.751 |
TGTX Liquidity
| Current Ratio | 4.102 |
| Quick Ratio | 3.285 |
| Cash Ratio | 0.923 |
TGTX Profitability
| Gross Margin | 83.658 |
| Operating Margin | 20.011 |
| Pretax Margin | 17.425 |
| Net Margin | 72.56 |
| Return on Assets | 54.503 |
| Return on Equity | 102.754 |
| Return on Total Capital | 49.591 |
| Return on Invested Capital | 65.015 |
TGTX Capital Structure
| Total Debt to Total Equity | 39.152 |
| Total Debt to Total Capital | 28.136 |
| Total Debt to Total Assets | 23.862 |
| Long-Term Debt to Equity | 38.99 |
| Long-Term Debt to Total Capital | 28.02 |